A novel pipeline for prioritizing cancer type‐specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas
Molecular Oncology · 2024-02 · 18 (2) · 336-349
DOI: 10.1002/1878-0261.13558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 13.12.2023. Verfasst von Malay K Sannigrahi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Head and Neck Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, NIDDK NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
There is limited guidance on exploiting the genome‐wide loss‐of‐function CRISPR screens in cancer Dependency Map (DepMap) to identify new targets for individual cancer types. This study integrated multiple tools to filter these data in order to seek new therapeutic targets specific to head and neck squamous cell carcinoma (HNSCC). The resulting pipeline prioritized 143 targetable dependencies that represented both well‐studied targets and emerging target classes like mitochondrial carriers and RNA‐binding proteins. In total, 14 targets had clinical inhibitors used for other cancers or nonmalignant diseases that hold near‐term potential to repurpose for HNSCC therapy. Comparing inhibitor response data that were publicly available for 13 prioritized targets between the cell lines with high vs. low dependency on each target uncovered novel therapeutic potential for the PAK2 serine/threonine kinase. PAK2 gene dependency was found to be associated with wild‐type p53, low PAK2 mRNA, and diploid status of the 3q amplicon containing PAK2 . These findings establish a generalizable pipeline to prioritize clinically relevant targets for individual cancer types using DepMap. Its application to HNSCC highlights novel relevance for PAK2 inhibition and identifies biomarkers of PAK2 inhibitor response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA, USA.
- Ellen and Ronald Caplan Cancer Center, The Wistar Institute, Philadelphia, PA, USA.
ORCID-Profile: Devraj Basu
Förderung
- NIDCR NIH HHS
- NIDDK NIH HHS
- NCI NIH HHS
- Division of Cancer Prevention, National Cancer Institute
- National Institute of Dental and Craniofacial Research
Zitieren
APA
Sannigrahi, M. K., Cao, A. C., Rajagopalan, P., Sun, L., Brody, R. M., Raghav, L., Gimotty, P. A., & Basu, D. (2024). A novel pipeline for prioritizing cancer type‐specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas. Molecular Oncology, 18(2), 336-349. https://doi.org/10.1002/1878-0261.13558
Vancouver
Sannigrahi MK, Cao AC, Rajagopalan P, Sun L, Brody RM, Raghav L, et al. A novel pipeline for prioritizing cancer type‐specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas. Molecular Oncology. 2024;18(2):336-349. doi:10.1002/1878-0261.13558
BibTeX
@article{Sannigrahi2024,
author = {Sannigrahi, Malay K and Cao, Austin C and Rajagopalan, Pavithra and Sun, Lova and Brody, Robert M and Raghav, Lovely and Gimotty, Phyllis A and Basu, Devraj},
title = {A novel pipeline for prioritizing cancer type‐specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas},
journal = {Molecular Oncology},
year = {2024},
volume = {18},
number = {2},
pages = {336--349},
doi = {10.1002/1878-0261.13558}
}
EUVIMED